Ohtuvayre (ensifentrine) is an inhaled prescription medication for adults with chronic obstructive pulmonary disease (COPD). As a phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitor, it’s used to help people breathe better in the long run. This medication is inhaled by mouth through a nebulizer with a fitted mouthpiece. It's taken two times each day, once in the morning and once in the evening. As a maintenance treatment, Ohtuvayre (ensifentrine) shouldn’t be used as a replacement for your inhaled rescue medication in case of sudden breathing problems. Side effects of Ohtuvayre (ensifentrine) include back pain, high blood pressure, and diarrhea.
Ohtuvayre (ensifentrine) is a phosphodiesterase 3 (PDE3) / phosphodiesterase 4 (PDE4) inhibitor. PDE3 and PDE4 are enzymes (proteins) in the body that control inflammation in the airways – they break down a chemical responsible for airway relaxation. So by blocking both PDE3 and PDE4, Ohtuvayre (ensifentrine) reduces inflammation and helps the muscles around the lungs stay relaxed. This helps lessen coughing, chest tightness, and trouble breathing.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Can start working as early as the first day of treatment
Can be used alongside other COPD treatments
Doesn’t commonly cause side effects
Must be taken twice daily
Risk of mental health problems
Must be inhaled using a nebulizer, which can be confusing to use for some people
Ohtuvayre (ensifentrine) is an inhaled medication to be used with a nebulizer only. Don’t swallow or inject this medication since it won’t work as it’s supposed to.
Even if your COPD symptoms get better, continue taking Ohtuvayre (ensifentrine) as prescribed. Your symptoms may come back after stopping the medication.
Contact your prescriber or get emergency medical attention right away if your breathing problems worsen. Also, be sure to reach out if you need to use your rescue inhaler more often than usual or if it no longer provides relief for your symptoms. These could be signs that Ohtuvayre (ensifentrine) isn’t working for you, and you might need a different medication.
Some people experience changes in their mood or behavior after starting Ohtuvayre (ensifentrine). If you notice symptoms like anxiety, depression, or suicidal thoughts and behaviors, seek medical help right away, as it could be life-threatening.
Store Ohtuvayre (ensifentrine) at room temperature in the unopened protective foil pouch. This will help protect the medication from sunlight or heat.
Don’t mix Ohtuvayre (ensifentrine) with other medications in the nebulizer. Doing so can change how the medication works and could potentially cause unwanted side effects.
How to use Ohtuvayre (ensifentrine):
Carefully read and follow the instructions for use before you first use Ohtuvayre (ensifentrine). Speak to your prescriber or pharmacist if you have any questions on how to take this medication correctly.
Ohtuvayre (ensifentrine) should only be used with a jet nebulizer with a mouthpiece.
Open the pouch and take out the ampule. Forcefully shake the ampule until the contents are mixed – the liquid should look cloudy and yellow in color.
Squeeze the medication out of the ampule into the nebulizer cup. Then throw away the empty ampule since it can be a choking hazard for children and pets.
Connect the mouthpiece to the nebulizer. Attach one end of the tubing to the compressor and the other end to the bottom of the nebulizer cup.
Sit upright and place the mouthpiece in your mouth. Close your lips around the mouthpiece.
Turn on the compressor to begin treatment. Breathe slowly and deeply until you don’t see anymore mist coming out of the nebulizer. This will take about 5 to 7 minutes.
Ohtuvayre (ensifentrine) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Ohtuvayre (ensifentrine) isn’t meant to stop sudden symptoms of COPD.Don’t take extra doses of the medication to relieve these symptoms. Instead, people should use a rescue inhaler such as albuterol to treat flare ups. Contact your prescriber if you find yourself using your rescue inhaler more, your rescue inhaler no longer relieves your symptoms, or your symptoms worsen after starting Ohtuvayre (ensifentrine). You may need to switch to a different medication.
Like other breathing treatments, Ohtuvayre (ensifentrine) can cause paradoxical bronchospasm, or unexpected tightening of the airways. This can be life threatening. If you start to feel sudden chest tightness or have trouble breathing, use your rescue inhaler right away to treat your symptoms. Stop using Ohtuvayre (ensifentrine) and let your prescriber know.
Risk factors: History of suicidal thoughts and behavior | History of anxiety or depression | History of insomnia
Ohtuvayre (ensifentrine) may be associated with mental health problems. Sometimes, these problems are serious, such as with suicidal thoughts and behavior. Other problems can include worsening insomnia, anxiety, or depression, and agitation. The risk for worsening mental health might be higher in those with a history of anxiety or depression, as well as prior thoughts of self-harm. If you or your loved ones notice a change in your mood or behavior, let your prescriber know immediately.
The typical dose is 3 mg (one ampule) inhaled by mouth twice daily, once in the morning and once in the evening. Use a nebulizer to inhale the medication.
Maintenance treatment for severe chronic obstructive pulmonary disease (COPD)
Maintenance treatment of chronic obstructive pulmonary disease (COPD)
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Anzueto, A., et al. (2023). Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: Randomized, double-blind, placebo-controlled, multicenter, phase III trials (the ENHANCE trials). American Journal of Respiratory and Critical Care Medicine.
Anzueto, A., et al. (n.d.). Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: Randomized, double-blind, placebo-controlled, multicenter, phase III trials (the ENHANCE trials): Online data supplement. American Journal of Respiratory and Critical Care Medicine.
Ayed, K., et al. (2020). Paradoxical bronchoconstriction caused by β2-adrenoceptor agonists. Drug Target Insights.
Beute, J., et al (2018). A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight.
Donohue, J. F., et al. (2023). Ensifentrine as a novel, inhaled treatment for patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease.
Li, H., et al. (2018). Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Frontiers in Pharmacology.
Verona Pharma, Inc. (2024). Instructions for use: Ohtuvayre (OH-too-vare) (ensifentrine) inhalation suspension, for oral inhalation [package insert]. DailyMed.
Verona Pharma, Inc. (2024). Ohtuvayre- ensifentrine suspension [package insert]. DailyMed.
Verona Pharma plc. (2024). Verona Pharma announces US FDA approval of Ohtuvayre™ (ensifentrine). Globe Newswire.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.